Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise its option on Kymera Therapeutics’ preclinical anticancer molecular glue degrader.
- Home |
- Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline
Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline
- April 9, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
